Form 10-K NEKTAR THERAPEUTICS For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Nektar Therapeutics (NKTR) Misses Q4 EPS by 2c
March 1, 2017 3:49 PM ESTNektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.28), $0.02 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $37.5 million versus the consensus estimate of $40.85 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
... More